Rexahn's Akt inhibitor increases pancreatic cancer survival time 50%
This article was originally published in Scrip
Executive Summary
Rexahn Pharmaceuticals potential first-in-class inhibitor of the Akt protein kinase in cancer cells, Archexin, provided metastatic pancreatic cancer with a survival rate that was more than 50% higher than historical rates for the standard of care. The data came from a 31-patient Phase IIa clinical trial. The Rockville, Maryland company will have to conduct a Phase IIb study in a larger pool of hard-to-treat patients to try to replicate the survival benefit.